GLP-1 drug market seen hitting $42B by 2035

The global GLP-1 drug market is projected to grow from $12.19 billion in 2025 to $42.0 billion by 2035, according to Market Research Future. The forecast points to rising obesity and diabetes rates, along with longer-acting and oral drug formats, as the main forces behind the expansion.

Why it matters: - GLP-1 drugs are becoming a bigger part of treatment for obesity, type 2 diabetes and cardiovascular risk. - The market's projected rise to $42.0 billion by 2035 signals continued demand for therapies that support weight loss, blood sugar control and easier dosing. - The shift matters for drugmakers, providers and payers as chronic disease treatment moves toward longer-acting and more convenient options.

What happened: - Market Research Future projected the global GLP-1 drug market will reach $42.0 billion by 2035. - The market is expected to rise from $12.19 billion in 2025, with a 13.17% compound annual growth rate through 2035. - The market base was estimated at $10.77 billion in 2024. - The forecast was published August 24, 2026. - The report cited rising obesity and type 2 diabetes, drug formulation advances and digital health adoption as the main growth drivers.

The details: - Long-acting GLP-1 formulations accounted for about 57% of market revenue in 2024. - Subcutaneous injection remained the dominant administration route with a 64% share in 2024. - Type 2 diabetes was the largest indication, with a 52% share in 2024. - Hospital pharmacies held a 46% share in 2024. - North America led the market with more than 50.14% of global revenue in 2024, or about $5.4 billion. - Europe was the second-largest regional market at $3.23 billion in 2024, representing a 30% share. - Asia-Pacific held about 15% of the global share. - The Middle East and Africa held about 5% of the global share. - More than 830 million people worldwide were living with diabetes in 2022, according to WHO data cited in the report. - High body mass index contributes to more than 160 million disability-adjusted life years globally, according to IHME data cited in the report. - Novo Nordisk generated about DKK 290.4 billion in 2024 revenue. - Eli Lilly reported about $45.0 billion in 2024 revenue. - Sanofi reported about EUR 41.8 billion in 2024 sales.

Between the lines: - The forecast points to a market shaped by chronic disease prevalence rather than a short-term product cycle. - Long-acting and oral formats are gaining traction because convenience and adherence can affect real-world outcomes. - Digital tools such as telehealth and mobile apps are becoming part of the treatment model, not just add-ons. - The market still appears moderately fragmented, with large drugmakers competing on formulation, access and regional expansion.

What's next: - Market Research Future sees the next phase of growth coming from emerging markets, combination therapies and digital health platforms. - Eli Lilly announced in August 2025 a collaboration with a technology firm to integrate artificial intelligence into drug development. - Sanofi launched a GLP-1 drug for the Asian market in September 2025. - Competition is likely to intensify as companies push into longer-acting, oral and region-specific products.

The bottom line: - GLP-1 drugs are moving from a fast-growing category into a major long-term metabolic disease market, with obesity and diabetes trends keeping demand elevated.